EMEA-002324-PIP01-17-M03
Key facts
| Invented name |
Kaftrio
|
| Active substance |
|
| Therapeutic area |
|
| Decision number |
P/0265/2022
|
| PIP number |
EMEA-002324-PIP01-17-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of cystic fibrosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Vertex Pharmaceuticals (Ireland) Limited
E-mail: vertexmedicalinfo@vrtx.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|